Valuation: Savara Inc.

Capitalization 1.28B 1.1B 1B 958M 1.76B 122B 1.78B 12.04B 4.66B 58.1B 4.79B 4.68B 202B P/E ratio 2026 *
-9.29x
P/E ratio 2027 * -14.7x
Enterprise value 1.28B 1.1B 1B 958M 1.76B 122B 1.78B 12.04B 4.66B 58.1B 4.79B 4.68B 202B EV / Sales 2026 *
402x
EV / Sales 2027 * 17.9x
Free-Float
97.37%
Yield 2026 *
-
Yield 2027 * -
05-12 Savara Q1 Loss Widens MT
05-12 Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss MT
05-12 Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating MT
04-15 Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP) RE
04-15 Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application MT
04-15 Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis CI
04-07 Savara Inc. Announces MHRA Accepts Molbreevi Marketing Authorisation Application for Autoimmune PAP CI
04-07 Savara Says UK Health Care Body Accepts Submission of Marketing Authorization Application for Molbreevi MT
04-07 Savara announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Molbreevi* marketing authorisation application (MAA) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) RE
03-30 Savara Says EMA Validates Marketing Authorization Application for Molbreevi to Treat Lung Disease MT
03-30 Savara Inc. Announces Validation Of Marketing Authorization Application For Molbreevi In Autoimmune Pulmonary Alveolar Proteinosis CI
03-13 Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 CI
1 day-4.55%
1 week-3.82%
Current month-4.01%
1 month-14.31%
3 months-10.18%
6 months+16.98%
Current year-16.58%
1 week 4.82
Extreme 4.82
5.42
1 month 4.82
Extreme 4.82
5.89
Current year 4.81
Extreme 4.81
6.49
1 year 1.89
Extreme 1.89
7
3 years 1.89
Extreme 1.89
7
5 years 1.02
Extreme 1.02
7
10 years 0.69
Extreme 0.69
17.19
Manager TitleAgeSince
Chief Executive Officer 55 30/11/2020
Director of Finance/CFO 58 31/10/2016
Chief Tech/Sci/R&D Officer - 30/11/2023
Director TitleAgeSince
Director/Board Member 58 31/01/2009
Director/Board Member 77 30/09/2010
Director/Board Member 72 30/09/2013
Change 5d. change 1-year change 3-years change Capi.($)
-4.55%-3.82%+61.74%+154.04% 1.34B
-0.14%+3.34%+42.69%+84.71% 50.39B
+0.12%-3.44%+67.99%+49.40% 46.03B
-5.60%+7.69%+62.36%+466.37% 25.06B
-2.65%-4.86%-3.02%-17.01% 23.26B
+3.19%+3.12%+41.22%-27.18% 17.24B
-1.66%+2.59%+30.04%-41.59% 16.15B
-2.91%-10.30%+47.85%+186.19% 14.56B
-7.00%-6.69%-26.94%+821.86% 14.08B
+0.41%-2.37%+40.93% - 12.94B
Average -2.08%-2.71%+36.49%+186.31% 22.11B
Weighted average by Cap. -1.43%-1.44%+40.26%+149.83%

Financials

2026 *2027 *
Net sales 3.18M 2.73M 2.5M 2.38M 4.37M 305M 4.44M 29.99M 11.6M 145M 11.92M 11.67M 504M 71.41M 61.45M 56.18M 53.6M 98.27M 6.85B 99.89M 674M 261M 3.25B 268M 262M 11.33B
Net income -139M -119M -109M -104M -191M -13.32B -194M -1.31B -507M -6.32B -521M -510M -22.03B -72.99M -62.81M -57.42M -54.79M -100M -7B -102M -689M -267M -3.32B -274M -268M -11.58B
Net Debt - -
Logo Savara Inc.
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
70
Date Price Change Volume
15/05/26 5.030 $ -4.55% 2,510,783
14/05/26 5.270 $ 0.00% 1,315,522
13/05/26 5.270 $ +3.74% 1,527,362
12/05/26 5.080 $ -0.78% 725,962
11/05/26 5.120 $ -2.10% 1,051,647
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.030USD
Average target price
10.81USD
Spread / Average Target
+114.96%

Quarterly revenue - Rate of surprise